by Dr. Gabe Mirkin | Jun 17, 2022 | Other Diseases & Conditions
Fourteen patients with “mismatched-repair” colorectal cancers were given a drug called dostarlimab every three weeks for six months, and follow-up after two years found that none of the patients had any remaining evidence of cancer (NEJM, June 5, 2022). This is an...
